8 news items
Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024
GILD
7 May 24
June 3, 2024
8:00 – 11:00 AM CDT
Gilead Sciences Announces First Quarter 2024 Financial Results
GILD
25 Apr 24
reports on Form 8-K. In addition, Gilead makes estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses
Gilead Sciences Announces Completion of Acquisition of CymaBay
CBAY
GILD
22 Mar 24
and Exchange Commission, including current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K. All forward-looking
Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender Offer
GILD
11 Mar 24
and Exchange Commission (the "SEC"), including current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K, as well
Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24
GILD
MRK
6 Mar 24
).
Initiation Option 2: Day 1: 600 mg orally (2 x 300-mg tablets). Day 2: 600 mg orally (2 x 300-mg tablets). Day 8: 300 mg orally (1 x 300-mg tablet). Day
8fxjb
GILD
5 Mar 24
, cerebrovascular disease, neuropsychiatric features, diarrhea, chest pain, and dysautonomia) and for 8 of 16 individual symptoms/diagnoses
0mqvic05mp9wou3v 0v9sc5m8svqcrt
GILD
5 Mar 24
profile, and maintained virologic suppression (HIV viral load ≤50 copies/mL) in 8/10 of participants. In addition, each of the six participants
bkk7kg8spqrrr61pgtsgi1rcrob0k95h43n18fpv5 auzc9uzuwfsa44
GILD
26 Feb 24
million patients around the world, including more than 8 million people in middle- and low-income countries through Gilead's voluntary licensing
- Prev
- 1
- Next